
The biotech IPO window is reopening, cautiously, and the terms have changed
Dr. Dereck Mush, MD, MBAConference
A strategic event examining drug development, clinical trial tech, and biotech dealmaking across the life sciences ecosystem.
Run by Questex, the event focuses on the intersection of drug discovery, digital clinical trials, and capital allocation. Executives from pharma, biotech, and research organizations gather to address clinical development bottlenecks. Key topics include using artificial intelligence in drug design, decentralizing trials, and navigating FDA regulatory changes. For technology operators, it provides a direct window into the product needs of pharmaceutical partners.
Biotech executives, pharmaceutical drug development leads, clinical trial tech vendors, and life science venture capitalists.
Launched by the editors of Fierce Biotech to bridge the gap between business strategy and scientific research. It has become a key autumn fixture for East Coast biotechnology leaders.
Running this event, or spotted something out of date?

Dr. Dereck Mush, MD, MBA
Dr. Dereck Mush, MD, MBA
Dr. Dereck Mush, MD, MBA
Dr. Dereck Mush, MD, MBAKeep exploring